Curcumin Inhibits Hypoxia-Inducible Factor-1 by Degrading Aryl Hydrocarbon Receptor Nuclear Translocator: A Mechanism of Tumor Growth Inhibition

Anticancer potential of curcumin: preclinical and clinical studies.

Bharat B. Aggarwal, Anushree Kumar, Alok C. Bharti · PubMed · 2003 · 2.6K citations

Medicine, Oncology, Pharmacology +15

Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases.

Hua Zhong, Angelo M. De Marzo, Erik Laughner et al. · PubMed · 1999 · 2.2K citations

Medicine, Cancer Biology, Oncology +14

Regulation of hypoxia-inducible factor 1α is mediated by an O ₂ -dependent degradation domain via the ubiquitin-proteasome pathway

Eric Huang, Jie Gu, Maureen Schau et al. · Proceedings of the National Academy of Sciences · 1998 · 2.1K citations · Full text

Life Sciences, Cell Biology, Molecular Biology +15

Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions.

Ann‐Lii Cheng, Chih‐Hung Hsu, Jen‐Kou Lin et al. · PubMed · 2001 · 2.1K citations

Medicine, Oncology, Pharmacology +10

Phase I Clinical Trial of Oral Curcumin

Ricky A. Sharma, Stephanie A. Euden, Sharon L. Platton et al. · Clinical Cancer Research · 2004 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +13